Literature DB >> 24012243

Neurocognitive speed associates with frontotemporal lobar degeneration TDP-43 subtypes.

Pamela M Dean1, Glenn E Smith, Joseph E Parisi, Dennis W Dickson, Ronald C Petersen, Keith A Josephs.   

Abstract

Frontotemporal lobar degeneration (FTLD) is pathologically heterogeneous with the TAR DNA binding protein 43 kDa (TDP-43) proteinopathy the most common substrate. Previous work has identified atrophy patterns across TDP-43 subtypes with Type A showing greater frontotemporal and parietal atrophy, Type C predominantly anterior temporal, and Type B predominantly posterior frontal. Despite neuroanatomical correlates of involvement, neuropsychological findings have been inconsistent. The current study utilized broader neurocognitive domains based on aggregated neuropsychological measures to distinguish between subtypes. We hypothesized that patterns of neurocognitive domain impairments would predict FTLD-TDP subtype. Fifty-one patients, aged 38-87, were identified post mortem with pathologically confirmed FTLD with TDP-43. Participants were classified into subtypes A, B, or C. Patients had completed neuropsychological assessments as part of their clinical evaluation. Six cognitive domains were created: Language; Cognitive Speed; Memory; Learning; Visuoperception; and Fluency. Binary logistic regression was conducted. All but three patients could be classified as FTLD-TDP Types A, B, or C: 26 as Type A; nine as Type B; and 13 as Type C. Cognitive Speed scores were associated with Types A and C (p < 0.001 and p = 0.003, respectively). Impaired performances on the Trail Making Test differentiated Types A and C. Worse Boston Naming Test and Logical Memory (Immediate) (p < 0.05) scores also increased the likelihood of Type C phenotype. Findings suggest Cognitive Speed associates with TDP-43 subtypes. Type C also demonstrated language-specific involvement. Differences between TDP-43 subtypes further supports the notion of differences in pathophysiology or topography across these types.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive speed; Dementia; Frontotemporal lobar degeneration; Neuropathology; Neuropsychology; TDP-43

Mesh:

Substances:

Year:  2013        PMID: 24012243      PMCID: PMC3825760          DOI: 10.1016/j.jocn.2013.01.024

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  25 in total

1.  Mayo's older African American normative studies: confirmatory factor analysis of a core battery.

Authors:  Otto Pedraza; John A Lucas; Glenn E Smith; Floyd B Willis; Neill R Graff-Radford; Tanis J Ferman; Ronald C Petersen; Dawn Bowers; Robert J Ivnik
Journal:  J Int Neuropsychol Soc       Date:  2005-03       Impact factor: 2.892

2.  Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies.

Authors:  Deepak M Sampathu; Manuela Neumann; Linda K Kwong; Thomas T Chou; Matthew Micsenyi; Adam Truax; Jennifer Bruce; Murray Grossman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

Review 3.  Neuropsychology of frontotemporal dementia.

Authors:  C M Kipps; J A Knibb; K Patterson; J R Hodges
Journal:  Handb Clin Neurol       Date:  2008

4.  Classification of primary progressive aphasia and its variants.

Authors:  M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

5.  Neuropsychological patterns in right versus left frontotemporal dementia.

Authors:  K B Boone; B L Miller; A Lee; N Berman; D Sherman; D T Stuss
Journal:  J Int Neuropsychol Soc       Date:  1999-11       Impact factor: 2.892

6.  Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration?

Authors:  J L Whitwell; C R Jack; J E Parisi; M L Senjem; D S Knopman; B F Boeve; R Rademakers; M Baker; R C Petersen; D W Dickson; K A Josephs
Journal:  Neurology       Date:  2010-12-14       Impact factor: 9.910

7.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

8.  Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations.

Authors:  Ian R A Mackenzie; Manuela Neumann; Eileen H Bigio; Nigel J Cairns; Irina Alafuzoff; Jillian Kril; Gabor G Kovacs; Bernardino Ghetti; Glenda Halliday; Ida E Holm; Paul G Ince; Wouter Kamphorst; Tamas Revesz; Annemieke J M Rozemuller; Samir Kumar-Singh; Haruhiko Akiyama; Atik Baborie; Salvatore Spina; Dennis W Dickson; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2008-11-18       Impact factor: 17.088

Review 9.  Neuropathological background of phenotypical variability in frontotemporal dementia.

Authors:  Keith A Josephs; John R Hodges; Julie S Snowden; Ian R Mackenzie; Manuela Neumann; David M Mann; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2011-05-26       Impact factor: 17.088

10.  Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Ankit V Master; Val J Lowe; Clifford R Jack; Jennifer L Whitwell
Journal:  Brain       Date:  2012-03-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.